The
Latest
The Latest
News
New Psychedelic Drug Formula Believed to Work to Mitigate Neurological Damage Due to Stroke, Provisional Patent Application Filed
News
Numinus Wellness Graduates to Tier 1 on the TSX Venture Exchange
News
Core One Labs Retains Canada’s Highest-Ranked IP Law Firm to Assist With Patent Filings
News
Cybin to Present at the Emerging Growth Conference on June 23rd
More Articles
FEATURED
Dr. Jennifer Miller | Principal Investigator, Tryp Therapeutics
News
Braxia Scientific Awarded Government of Canada Funding to Complete First of its Kind Ketamine Clinical Trial for Bipolar Depression
News
Ketamine One Highlights Psychedelic Research And Announces New Clinical Trial
Trending
#
News
Myconic Capital to Acquire KGK Science From Auxly Cannabis Group
#
News
Ketamine One Signs Definitive Agreement to Acquire Integrated Rehab and Performance Ltd.
#
News
Pierre Bou-Mansour, P. Eng. | COO, Novamind
#
News
IntelGenx’s VetaFilm™ Platform to be Evaluated by One of the World’s Fastest Growing Animal Healthcare Companies
#
News
MindMed Announces Chief Executive Officer Transition
Companies
#
Tryp Therapeutics
NEO
NASDAQ
CSE
TSXV
Private Company
#
Cybin Corp
NEO
NASDAQ
CSE
TSXV
Private Company
#
Field Trip Health
NEO
NASDAQ
CSE
TSXV
Private Company
#
Numinus
NEO
NASDAQ
CSE
TSXV
Private Company
#
Mydecine Innovations Group
NEO
NASDAQ
CSE
TSXV
Private Company
Features
News
New Psychedelic Drug Formula Believed to Work to Mitigate Neurological Damage Due to Stroke, Provisional Patent Application Filed
News
Numinus Wellness Graduates to Tier 1 on the TSX Venture Exchange
News
Core One Labs Retains Canada’s Highest-Ranked IP Law Firm to Assist With Patent Filings
News
Cybin to Present at the Emerging Growth Conference on June 23rd
© year Psychedelic Finance